Background: Respiratory alemtuzumab-related adverse events are clinically heterogeneous and include respiratory infections, infusion-related dyspnea, hypoxia and secondary autoimmune disorders. Case report: Here we report three cases of drug-induced lung disease following treatment with alemtuzumab in multiple sclerosis patients. First case was diagnosed as a non-specified intestitial pneumonitis associated with organizing pneumonia with subacute onset, second case was an acute respiratory distress syndrome with onset during second cycle, third case was a diffuse acute alveolar hemorrhage during first cycle infusion. All patients developed acute respiratory failure, reversible after steroid therapy. Conclusions: Clinicians should be aware to early recognize acute and subacute respiratory adverse events for a promptly management. In these patients re-treatment is challenging.

Bianco, A., Mari, P., Larici, A. R., Lucchini, M., Nociti, V., Losavio, F. A., De Fino, C., Cicchetti, G., Coraci, D., Richeldi, L., Mirabella, M., Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients, <<MULTIPLE SCLEROSIS AND RELATED DISORDERS>>, 2019; 37 (37): 1-3. [doi:10.1016/j.msard.2019.101450] [http://hdl.handle.net/10807/147357]

Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients

Bianco, Assunta
Primo
;
Mari, Pier-Valerio
Secondo
;
Larici, Anna Rita;Lucchini, Matteo;Nociti, Viviana;Losavio, Francesco Antonio;De Fino, Chiara;Cicchetti, Giuseppe;Coraci, Daniele;Richeldi, Luca
Penultimo
;
Mirabella, Massimiliano
2020

Abstract

Background: Respiratory alemtuzumab-related adverse events are clinically heterogeneous and include respiratory infections, infusion-related dyspnea, hypoxia and secondary autoimmune disorders. Case report: Here we report three cases of drug-induced lung disease following treatment with alemtuzumab in multiple sclerosis patients. First case was diagnosed as a non-specified intestitial pneumonitis associated with organizing pneumonia with subacute onset, second case was an acute respiratory distress syndrome with onset during second cycle, third case was a diffuse acute alveolar hemorrhage during first cycle infusion. All patients developed acute respiratory failure, reversible after steroid therapy. Conclusions: Clinicians should be aware to early recognize acute and subacute respiratory adverse events for a promptly management. In these patients re-treatment is challenging.
2020
Inglese
Bianco, A., Mari, P., Larici, A. R., Lucchini, M., Nociti, V., Losavio, F. A., De Fino, C., Cicchetti, G., Coraci, D., Richeldi, L., Mirabella, M., Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients, <<MULTIPLE SCLEROSIS AND RELATED DISORDERS>>, 2019; 37 (37): 1-3. [doi:10.1016/j.msard.2019.101450] [http://hdl.handle.net/10807/147357]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/147357
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 8
social impact